Brain Cancer
Peregrine Pharmaceuticals Initiates Patient Enrollment In New Cotara Brain Cancer Trial
Published in Cancer Weekly, July 10th, 2007
Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM), a clinical stage biopharmaceutical company developing targeted monoclonal antibodies for the treatment of cancer and hepatitis C virus infection, announced initiation of a new clinical trial designed to evaluate the safety and efficacy of its tumor necrosis therapy (TNT) agent Cotara(R) in patients with glioblastoma multiforme (GBM), a deadly form of brain cancer. In pilot studies Cotara has shown encouraging results, demonstrating a 58% increase in the expected median survival time in a group of 28 patients suffering from recurrent late stage glioblastoma multiforme. This was considered a promising development in this serious and deadly...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2007-07-10)
More Articles from Cancer Weekly
- Angiogenesis
GammaCan Discovers Anti-Angiogenic Properties in Plasma-Derived IgG - Asthma
Massachusetts Health Quality Partners Issues 2007 Report on Medical Group Quality-of-Care - Bird Flu
Carrington Subsidiary DelSite Predicts Preservative-Free Vaccines in World's Future - Brain Cancer
Medical University of South Carolina Initiates New Trial of Cotara in Brain Cancer Patients - Breast Cancer
American Telecom Announces New Give N' Talk Distribution Through the Most Fashion Oriented Mass Merchant in the U.S. - Breast Cancer
Breast Cancer Survivor Diagnosed at 36 Turns to Photographing Surgery as a Way of Inspiring Cancer Survivors and Honoring Medical Teams Dedicated to Saving Lives - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
